ARTICLE | Clinical News
Collateral to begin Phase IIb/III
June 18, 2001 7:00 AM UTC
CLTX and partner Schering (SHR) will begin shortly double-blind, placebo-controlled Phase IIb/III trials in the U.S. and Europe of Ad5FGF4 gene therapy to treat patients with stable exertional angina ...